JP6255346B2 - 癌治療のための治療用組合せ - Google Patents
癌治療のための治療用組合せ Download PDFInfo
- Publication number
- JP6255346B2 JP6255346B2 JP2014537346A JP2014537346A JP6255346B2 JP 6255346 B2 JP6255346 B2 JP 6255346B2 JP 2014537346 A JP2014537346 A JP 2014537346A JP 2014537346 A JP2014537346 A JP 2014537346A JP 6255346 B2 JP6255346 B2 JP 6255346B2
- Authority
- JP
- Japan
- Prior art keywords
- oleander
- cisplatin
- extract
- therapeutic composition
- species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001225 therapeutic effect Effects 0.000 title claims description 54
- 206010028980 Neoplasm Diseases 0.000 title claims description 24
- 201000011510 cancer Diseases 0.000 title claims description 20
- 238000011282 treatment Methods 0.000 title description 8
- 229960004316 cisplatin Drugs 0.000 claims description 61
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 61
- 239000000284 extract Substances 0.000 claims description 46
- 244000187664 Nerium oleander Species 0.000 claims description 43
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 38
- 241000893864 Nerium Species 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- 229910052697 platinum Inorganic materials 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 229960004562 carboplatin Drugs 0.000 claims description 8
- 190000008236 carboplatin Chemical compound 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 229960001756 oxaliplatin Drugs 0.000 claims description 8
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 8
- 229960005399 satraplatin Drugs 0.000 claims description 8
- 190014017285 satraplatin Chemical compound 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 229950007221 nedaplatin Drugs 0.000 claims description 7
- 229950005566 picoplatin Drugs 0.000 claims description 7
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 190000005734 nedaplatin Chemical compound 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 59
- 238000002835 absorbance Methods 0.000 description 46
- 238000000034 method Methods 0.000 description 38
- JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 description 36
- 238000011534 incubation Methods 0.000 description 28
- 238000003556 assay Methods 0.000 description 22
- 239000013078 crystal Substances 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 12
- 239000000975 dye Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OMAFFHIGWTVZOH-UHFFFAOYSA-O 1-methyl-2h-tetrazol-1-ium Chemical compound C[N+]1=CN=NN1 OMAFFHIGWTVZOH-UHFFFAOYSA-O 0.000 description 8
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 6
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 5
- 241001116389 Aloe Species 0.000 description 5
- 235000011399 aloe vera Nutrition 0.000 description 5
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010972 statistical evaluation Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- JLPDBLFIVFSOCC-UHFFFAOYSA-N Oleandrin Natural products O1C(C)C(O)C(OC)CC1OC1CC(CCC2C3(CC(C(C3(C)CCC32)C=2COC(=O)C=2)OC(C)=O)O)C3(C)CC1 JLPDBLFIVFSOCC-UHFFFAOYSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229950010050 oleandrin Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- IWCNCUVTGOMGKG-UHFFFAOYSA-N 5alpha-oleandrigenin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C1=CC(=O)OC1 IWCNCUVTGOMGKG-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- IWCNCUVTGOMGKG-YOVVEKLRSA-N oleandrigenin Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)=CC(=O)OC1 IWCNCUVTGOMGKG-YOVVEKLRSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549386P | 2011-10-20 | 2011-10-20 | |
| US61/549,386 | 2011-10-20 | ||
| PCT/US2012/061226 WO2013059753A1 (en) | 2011-10-20 | 2012-10-20 | Therapeutic combination for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530878A JP2014530878A (ja) | 2014-11-20 |
| JP6255346B2 true JP6255346B2 (ja) | 2017-12-27 |
Family
ID=48141445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537346A Expired - Fee Related JP6255346B2 (ja) | 2011-10-20 | 2012-10-20 | 癌治療のための治療用組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130209579A1 (enExample) |
| EP (2) | EP3711754A1 (enExample) |
| JP (1) | JP6255346B2 (enExample) |
| CN (2) | CN104093405A (enExample) |
| AU (3) | AU2012325819B2 (enExample) |
| BR (1) | BR112014009421A2 (enExample) |
| CA (1) | CA2852274C (enExample) |
| GT (1) | GT201400071A (enExample) |
| IL (2) | IL231987B (enExample) |
| IN (1) | IN2014KN00796A (enExample) |
| MX (2) | MX365635B (enExample) |
| RU (2) | RU2014120179A (enExample) |
| WO (1) | WO2013059753A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5727934B2 (ja) * | 2008-10-14 | 2015-06-03 | ネリウム バイオテクノロジー、インク． | 強心配糖体抽出プロセスおよび組成物 |
| AU2016250616B2 (en) * | 2015-04-22 | 2021-01-21 | Syn-Nat Products Enterprise LLC | Co-crystal composition and its pharmaceutical use |
| EA037248B1 (ru) * | 2015-10-05 | 2021-02-26 | НУКАНА ПиЭлСи | Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1299100C (en) | 1986-05-13 | 1992-04-21 | Huseyin Ziya Ozel | Extracts of nerium species, methods of preparation and use therefor |
| US6565897B2 (en) | 1998-09-24 | 2003-05-20 | Ozelle Pharmaceuticals, Inc. | Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof |
| US7407675B2 (en) * | 2002-12-27 | 2008-08-05 | The Trustees Of Columbia University In The City Of New York | Anti-neoplastic compositions comprising extracts of black cohosh |
| US20060205679A1 (en) * | 2004-10-22 | 2006-09-14 | Azaya Therapeutics, Inc. | Topical and oral formulations of cardiac glycosides for treating skin diseases |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| EP1803461A1 (en) * | 2005-12-27 | 2007-07-04 | Heinz-Herbert Fiebig | Therapeutic use of an extract from the leaves of Nerium oleander |
| PL2173337T3 (pl) | 2007-08-06 | 2014-11-28 | Univ Ohio | Fosfaplatyny i ich zastosowanie w leczeniu raków opornych na cisplatynę i karboplatynę |
| JP5727934B2 (ja) * | 2008-10-14 | 2015-06-03 | ネリウム バイオテクノロジー、インク． | 強心配糖体抽出プロセスおよび組成物 |
-
2012
- 2012-10-20 CA CA2852274A patent/CA2852274C/en not_active Expired - Fee Related
- 2012-10-20 EP EP20159407.4A patent/EP3711754A1/en not_active Withdrawn
- 2012-10-20 WO PCT/US2012/061226 patent/WO2013059753A1/en not_active Ceased
- 2012-10-20 RU RU2014120179/15A patent/RU2014120179A/ru unknown
- 2012-10-20 BR BR112014009421A patent/BR112014009421A2/pt not_active Application Discontinuation
- 2012-10-20 RU RU2017136415A patent/RU2017136415A/ru not_active Application Discontinuation
- 2012-10-20 CN CN201280051254.5A patent/CN104093405A/zh active Pending
- 2012-10-20 IN IN796KON2014 patent/IN2014KN00796A/en unknown
- 2012-10-20 AU AU2012325819A patent/AU2012325819B2/en not_active Ceased
- 2012-10-20 JP JP2014537346A patent/JP6255346B2/ja not_active Expired - Fee Related
- 2012-10-20 CN CN201910226194.XA patent/CN110269940A/zh active Pending
- 2012-10-20 MX MX2014004527A patent/MX365635B/es active IP Right Grant
- 2012-10-20 EP EP12841023.0A patent/EP2768498B1/en active Active
-
2013
- 2013-03-15 US US13/838,739 patent/US20130209579A1/en not_active Abandoned
-
2014
- 2014-04-07 IL IL231987A patent/IL231987B/en not_active IP Right Cessation
- 2014-04-14 MX MX2019006685A patent/MX2019006685A/es unknown
- 2014-04-15 GT GT201400071A patent/GT201400071A/es unknown
-
2017
- 2017-10-31 AU AU2017254875A patent/AU2017254875A1/en not_active Abandoned
-
2019
- 2019-05-21 AU AU2019203577A patent/AU2019203577A1/en not_active Abandoned
- 2019-05-22 US US16/419,226 patent/US20190343908A1/en not_active Abandoned
-
2020
- 2020-06-24 IL IL275636A patent/IL275636A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL231987A0 (en) | 2014-05-28 |
| MX2014004527A (es) | 2014-09-15 |
| EP2768498A1 (en) | 2014-08-27 |
| MX365635B (es) | 2019-06-10 |
| NZ623550A (en) | 2016-06-24 |
| EP2768498A4 (en) | 2015-06-17 |
| IL231987B (en) | 2020-07-30 |
| IN2014KN00796A (enExample) | 2015-10-02 |
| AU2012325819B2 (en) | 2017-08-03 |
| AU2017254875A1 (en) | 2017-11-23 |
| EP2768498B1 (en) | 2020-03-04 |
| GT201400071A (es) | 2015-09-17 |
| CA2852274C (en) | 2019-08-06 |
| WO2013059753A1 (en) | 2013-04-25 |
| CN104093405A (zh) | 2014-10-08 |
| BR112014009421A2 (pt) | 2017-04-18 |
| RU2017136415A3 (enExample) | 2021-02-08 |
| US20190343908A1 (en) | 2019-11-14 |
| AU2012325819A1 (en) | 2014-04-24 |
| RU2017136415A (ru) | 2019-02-08 |
| CA2852274A1 (en) | 2013-04-25 |
| RU2014120179A (ru) | 2015-11-27 |
| IL275636A (en) | 2020-08-31 |
| AU2019203577A1 (en) | 2019-06-13 |
| US20130209579A1 (en) | 2013-08-15 |
| EP3711754A1 (en) | 2020-09-23 |
| CN110269940A (zh) | 2019-09-24 |
| JP2014530878A (ja) | 2014-11-20 |
| MX2019006685A (es) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway | |
| Liang et al. | The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair | |
| Sinha et al. | Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo | |
| Li et al. | Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer | |
| Guan et al. | Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro | |
| Wang et al. | Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene | |
| Zhao et al. | Effect of pristimerin on apoptosis through activation of ROS/endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer | |
| Peng et al. | Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling | |
| Zhang et al. | Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma | |
| JP2016519076A (ja) | マイクロｒｎａ及びｅｇｆｒ−ｔｋｉ阻害剤を利用する癌の併用処置 | |
| Wang et al. | XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy | |
| Kim et al. | Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress | |
| Kim et al. | A novel herbal medicine, KIOM-C, induces autophagic and apoptotic cell death mediated by activation of JNK and reactive oxygen species in HT1080 human fibrosarcoma cells | |
| Chen et al. | The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway | |
| Liu et al. | HIV protease inhibitors sensitize human head and neck squamous carcinoma cells to radiation by activating endoplasmic reticulum stress | |
| Peng et al. | Dual inhibition of pirarubicin-induced AKT and ERK activations by phenformin sensitively suppresses bladder cancer growth | |
| Chen et al. | Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells | |
| US20190343908A1 (en) | Therapeutic Combination for the Treatment of Cancer | |
| Xie et al. | Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma | |
| Putri et al. | Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells | |
| Früh et al. | Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08) | |
| Wu et al. | Antitumor effect of ginsenoside Rg3 on gallbladder cancer by inducing endoplasmic reticulum stress-mediated apoptosis in vitro and in vivo | |
| Wang et al. | Dual PI3K/HDAC inhibitor BEBT-908 exhibits potent efficacy as monotherapy for primary central nervous system lymphoma | |
| Kim et al. | Akt3 knockdown induces mitochondrial dysfunction in human cancer cells | |
| Lei et al. | Epigallocatechin-3-gallate induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151001 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160923 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170411 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170705 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171114 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171204 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6255346 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |